Table 5 Recommendations for CMR in the guidelines on cardio-oncology

Recommendations for cardiac imaging modalities in patients with cancer

CMR should be considered for the assessment of cardiac function when echocardiography is unavailable or non-diagnostic

IIa

C

Recommendations for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis

Cardiac Troponin (cTn), ECG, and cardiovascular imaging (echocardiography and CMR) are recommended to diagnose immune checkpoint inhibitor (ICI)—associated myocarditis

I

B

Recommendations for the diagnosis and management of Takotsubo syndrome in patients with cancer

CMR is recommended to exclude myocarditis and myocardial infarction

I

B

Recommendations for the management of pericardial diseases in patients receiving anticancer treatment

Multimodality cardiovascular imaging (echocardiography, CMR ± CT), ECG and measurement of cardiac biomarkers are recommended to confirm the diagnosis, assess the hemodynamic consequences of pericardial disease, and rule out associated myocarditis

I

C

Recommendations for amyloid light-chain cardiac amyloidosis diagnosis and monitoring

CMR is recommended in patients with suspected amyloid light-chain cardiac amyloidosis (AL-CA)

I

A